parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in myonuclei	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 48	0.85
pathways Reactome	1 pathway; mostly immune signalling	0.90

No case: the score is under the bar. Receipt 11721

UBE2E2 in microglia, braak+0.00 (p 1.000) → -0.13 (p 0.735)receipt 11728
UBE2E2 in dopamine neurons, braak+0.29 (p 0.457) → -0.07 (p 0.856)receipt 11729

receipt 11729: UBE2E2 in dopamine neurons, braak

power: full sample +0.07 (p 0.794, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.800, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.956, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.19, sign flips 2; without severely affected donors +0.07 (p 0.794, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for UBE2E2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11728: UBE2E2 in microglia, braak

power: full sample -0.01 (p 0.983, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.854, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.03 (p 0.908, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.13, sign flips 6; without severely affected donors -0.01 (p 0.983, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for UBE2E2 in microglia.

case closed: nothing better to follow up.

loading the receipts